FDA Approves Canakinumab for Adult-Onset Still’s Disease
Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks
